Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ruanshang Pian
- Development stage
- Phase 2
- Lead developer
- Liaoning University of Traditional Chinese Medicine
- Administration
- Oral
01
Overview
Ruanshang Pian is a Traditional Chinese Medicine (TCM) formulation developed by the Liaoning University of Traditional Chinese Medicine and the Institute of Chinese Materia Medica. It is specifically designed for the treatment of acute closed soft tissue injuries, particularly those presenting with the TCM syndrome of Qi stagnation and blood stasis. The medication is formulated as an oral tablet. Clinical development has reached Phase II, where studies have focused on evaluating its efficacy in symptom relief and safety profile, as well as determining the optimal therapeutic dosage for soft tissue trauma.
- Brand names
- Ruanshang Pian
- Other names
- Ruanshang tablets
02
Targets
IL1A (Interleukin 1 alpha)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Ruanshang Pian.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ruanshang Pian.